CTBO (Cantabio Pharmaceuticals) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2018)


What is Cantabio Pharmaceuticals LT-Debt-to-Total-Asset?

Cantabio Pharmaceuticals CTBO LT-Debt-to-Total-Asset is 0.00 as of Dec. 2018.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cantabio Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2018 was 0.00.

Cantabio Pharmaceuticals's long-term debt to total assets ratio stayed the same from Dec. 2017 (0.00) to Dec. 2018 (0.00).

Cantabio Pharmaceuticals  (OTCPK:CTBO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cantabio Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Cantabio Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals LT-Debt-to-Total-Asset Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cantabio Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Cantabio Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2018 is calculated as

LT Debt to Total Assets (A: Mar. 2018 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2018 )/Total Assets (A: Mar. 2018 )
=0/0.109
=

Cantabio Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (Q: Dec. 2018 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2018 )/Total Assets (Q: Dec. 2018 )
=0/0.326
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Cantabio Pharmaceuticals (CTBO) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2018. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Cantabio Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.00.
How does Cantabio Pharmaceuticals' LT-Debt-to-Total-Asset compare to TNTY and ETNI?
Cantabio Pharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.